TNF-α promotes human retinal pigment epithelial (RPE) cell migration by inducing matrix metallopeptidase 9 (MMP-9) expression through activation of Akt/mTORC1 signaling

Biochemical and Biophysical Research Communications

Volumn 425, Issue 1, 2012, Pages 33-38

  Wang, Cheng hu ^a   Cao, Guo Fan ^a   Jiang, Qin ^a   Yao, Jin ^a  

^a First Affiliated Hospital of Nanjing Medical University   (China)

Author keywords

Akt mTOR signaling; MMP 9; RPE cell migration; TNF

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; GELATINASE B; LINSIDOMINE; PROTEIN KINASE B; RAPAMYCIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL MIGRATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA DETACHMENT; RNA INTERFERENCE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL MOVEMENT; CELLS, CULTURED; HUMANS; MATRIX METALLOPROTEINASE 9; PIGMENT EPITHELIUM OF EYE; PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR NECROSIS FACTOR-ALPHA; VITREORETINOPATHY, PROLIFERATIVE;

EID: 84865176634     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.07.044     Document Type: Article

References (34)

1. Gilbert C., Hiscott P., Unger W., et al. Inflammation and the formation of epiretinal membranes. Eye (London) 1988, 2(Suppl):S140-S156.
2. Charteris D.G. Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br. J. Ophthalmol. 1995, 79:953-960.
3. Pastor J.C. Proliferative vitreoretinopathy: an overview. Surv. Ophthalmol. 1998, 43:3-18.
4. Joeres S., Kirchhof B., Joussen A.M. PVR as a complication of rhegmatogeneous retinal detachment: a solved problem?. Br. J. Ophthalmol. 2006, 90:796-797.
5. Lewis H., Aaberg T.M. Causes of failure after repeat vitreoretinal surgery for recurrent proliferative vitreoretinopathy. Am. J. Ophthalmol. 1991, 111:15-19.
6. Girard P., Mimoun G., Karpouzas I., et al. Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery. Retina 1994, 14:417-424.
7. Limb G.A., Alam A., Earley O., et al. Distribution of cytokine proteins within epiretinal membranes in proliferative vitreoretinopathy. Curr. Eye Res. 1994, 13:791-798.
8. Limb G.A., Little B.C., Meager A., et al. Cytokines in proliferative vitreoretinopathy. Eye (London) 1991, 5(Pt 6):686-693.
9. Campochiaro P.A. Pathogenic mechanisms in proliferative vitreoretinopathy. Arch. Ophthalmol. 1997, 115:237-241.
10. Kirchhof B. Strategies to influence PVR development. Graefes Arch. Clin. Exp. Ophthalmol. 2004, 242:699-703.
11. Canataroglu H., Varinli I., Ozcan A.A., et al. Interleukin (IL)-6, interleukin (IL)-8 levels and cellular composition of the vitreous humor in proliferative diabetic retinopathy, proliferative vitreoretinopathy, and traumatic proliferative vitreoretinopathy. Ocul. Immunol. Inflamm. 2005, 13:375-381.
12. Hiscott P., Sheridan C., Magee R.M., et al. Matrix and the retinal pigment epithelium in proliferative retinal disease. Prog. Retin. Eye Res. 1999, 18:167-190.
13. Scott K.A., Arnott C.H., Robinson S.C., et al. TNF-alpha regulates epithelial expression of MMP-9 and integrin alphavbeta6 during tumour promotion. A role for TNF-alpha in keratinocyte migration?. Oncogene 2004, 23:6954-6966.
14. French K.J., Schrecengost R.S., Lee B.D., et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003, 63:5962-5969.
15. Robinson S.C., Scott K.A., Balkwill F.R. Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alpha. Eur. J. Immunol. 2002, 32:404-412.
16. Swanton C., Marani M., Pardo O., et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 2007, 11:498-512.
17. Chipuk J.E., Kuwana T., Bouchier-Hayes L., et al. Direct activation of bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004, 303:1010-1014.
18. Buck E., Eyzaguirre A., Brown E., et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol. Cancer Ther. 2006, 5:2676-2684.
19. Dennis P.B., Jaeschke A., Saitoh M., et al. Mammalian TOR: a homeostatic ATP sensor. Science 2001, 294:1102-1105.
20. Dudkin L., Dilling M.B., Cheshire P.J., et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin. Cancer Res. 2001, 7:1758-1764.
21. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
22. Sabatini D.M. MTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 2006, 6:729-734.
23. Y. Liu, G.F. Cao, J. Xue, et al., Tumor necrosis factor-alpha (TNF-alpha)-mediated in vitro human retinal pigment epithelial (RPE) cell migration mainly requires Akt/mTOR complex 1 (mTORC1), but not mTOR complex 2 (mTORC2) signaling, Eur. J. Cell Biol. (2012). [Epub ahead of print].
24. Cao G.F., Liu Y., Yang W., et al. Rapamycin sensitive mTOR activation mediates nerve growth factor (NGF) induced cell migration and pro-survival effects against hydrogen peroxide in retinal pigment epithelial cells. Biochem. Biophys. Res. Commun. 2011, 414:499-505.
25. Albrecht-Buehler G. The phagokinetic tracks of 3T3 cells. Cell 1977, 11:395-404.
26. Tracey K.J., Cerami A. Tumor necrosis factor: an updated review of its biology. Crit. Care Med. 1993, 21:S415-S422.
27. Zhang D., Brodt P. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene 2003, 22:974-982.
28. Chen J.S., Wang Q., Fu X.H., et al. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol. Res. 2009, 39:177-186.
29. Zhou H.Y., Wong A.S. Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. Endocrinology 2006, 147:2557-2566.
30. Seeliger H., Guba M., Kleespies A., et al. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev. 2007, 26:611-621.
31. Meng Q., Xia C., Fang J., et al. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell. Signal. 2006, 18:2262-2271.
32. Rhoads J.M., Niu X., Odle J., et al. Role of mTOR signaling in intestinal cell migration. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 291:G510-G517.
33. Liu L., Li F., Cardelli J.A., et al. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene 2006, 25:7029-7040.
34. Poon M., Marx S.O., Gallo R., et al. Rapamycin inhibits vascular smooth muscle cell migration. J. Clin. Invest. 1996, 98:2277-2283.